New combo tackles liver cancer when standard treatment stops working
NCT ID NCT07192185
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding FOLFOX chemotherapy to the existing immunotherapy drugs atezolizumab and bevacizumab can help patients with advanced liver cancer whose disease has worsened on first-line treatment. The study will enroll 30 adults with Barcelona Clinic Liver Cancer stage C. Researchers will measure how many patients' tumors shrink and how long they live overall.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FOLFOX chemotherapy (oxaliplatin, leucovorin, 5-fluorouracil) plus atezolizumab and bevacizumab
What this could lead to
If successful, this could offer a new second-line treatment option for advanced liver cancer patients who have stopped responding to standard first-line therapy.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply broadly. Adding chemotherapy to immunotherapy also increases the risk of side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••